Roche (SWX:ROG), InterMune, Inc. (Nasdaq: ITMN) and Pharmasset (Nasdaq: VRUS) today announced that the first patients have been dosed in an innovative clinical trial in patients chronically infected with the hepatitis C virus (HCV). The trial (run in centers in Australia and New Zealand) is the first to investigate the combination of two oral antiviral molecules in the absence of interferon.
Navigation
Daily News
- Health ad campaigns emerge in final days of debate
- BioVigil’s second generation hand hygiene monitoring system released
- Antiseptic Baths Help Fight ‘Superbug’ Infections
- Women and Hair Loss
- Slate Looks At ‘Contraceptive Pioneers’ And New Contraceptives In Development
Translator
 |  |  |  |  |  |  |  |  |  |
 |  |  |  |  |  |  |  |  |  |
 |  |  |  |  |  |  |  | ||
| By N2H | |||||||||